Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

L Cummings, Jeffrey; G Lyketsos, Constantine; R Peskind, Elaine; P Porsteinsson, Anton; E Mintzer, Jacobo; W Scharre, Douglas; E De La Gandara, Jose; Agronin, Marc; S Davis, Charles; Nguyen, Uyen; Shin, Paul; N Tariot, Pierre; Siffert, João

doi:10.1001/jama.2015.10214

Public

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Published in JAMA • 2026

NobleIDark:/48914/w1/20260526/D7562564Record on NobleID

Authors:

Jeffrey L Cummings

,

Constantine G Lyketsos

,

Elaine R Peskind

Abstract

IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Ph...

Discussions